References
- Ames, B.N., McCann, J., and Yamasaki, E., 1975. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutation Research/Environmental Mutagenesis and Related Subjects, 31 (6), 347–364.
- Brambilla, G., et al., 2010. Genotoxicity and carcinogenicity testing of pharmaceuticals: correlations between induction of DNA lesions and carcinogenic activity. Mutation Research, 705 (1), 20–39.
- Frazzoni, L., Fuccio, L., and Frazzoni, M., 2017. Proton pump inhibitor-refractory gastroesophageal reflux disease: current diagnosis and management. Minerva Gastroenterologica e Dietologica, 63 (3), 249–256.
- Giovanni, B., Francesca, M., and Antonietta, M., 2010. Genotoxic and carcinogenic effects of gastrointestinal drugs. Mutagenesis, 25 (4), 315–326.
- ICH M7(R1), 2016. Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk [online]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_R1_Addendum_Step_4_2017_0031.pdf [Accessed 10 November 2016].
- Marchant, C.A., Briggs, K.A., and Long, A., 2008. In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for Windows, Meteor, and Vitic. Toxicology Mechanisms and Methods, 18 (2–3), 177–187.
- Mombelli, E., Raitano, G., and Benfenati, E., 2016. In silico prediction of chemically induced mutagenicity: how to use QSAR models and interpret their results. Methods in Molecular Biology (Clifton, N.J.), 1425, 87–105.
- Müller, L., et al., 2006. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regulatory Toxicology and Pharmacology, 44 (3), 198–211.
- NLM, 2020a. Rabeprazole. 1962–2020 [online]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/rabeprazole#section=Top [Accessed 12 October 2001].
- NLM, 2020b. Toxnet, toxicology data network. 1962–2020 [online]. Available from: http://www.toxnet.nlm.nih.gov [Accessed 24 April 2006].
- Paz, M.F.C.J., et al., 2020. Pharmacological effects and toxicogenetic impacts of omeprazole: genomic instability and cancer. Oxidative Medicine and Cellular Longevity, 2020, 3457890.
- Rao, P.S., et al., 2010. Identification, isolation and characterization of new impurity in rabeprazole sodium. Journal of Pharmaceutical and Biomedical Analysis, 52 (4), 620–624.
- Reddy, G.M., et al., 2007. Identification and characterization of potential impurities of rabeprazole sodium. Journal of Pharmaceutical and Biomedical Analysis, 43 (4), 1262–1269.
- Robinson, M. and Horn, J., 2003. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs, 63 (24), 2739–2754.
- Thomson, P.D.R. and Montvale, N.J., 2005. Physicians’ desk reference. 59th ed. New York: Physicians’ Desk Reference.
- Valencia, A., et al., 2013. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities. Toxicology and Applied Pharmacology, 273 (3), 427–434.
- Yenugu, V.M.R., et al., 2018. A simple, sensitive, and straightforward LC–MS approach for rapid analysis of three potential genotoxic impurities in rabeprazole formulations. Journal of Separation Science, 41 (21), 3966–3973.